Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against *Staphylococcus aureus* *

Adam Belley, Eve Neesham-Grenon, Francis F. Arhin, Geoffrey A. McKay, Thomas R. Parr, Jr., and Gregory Moeck* 

Targanta Therapeutics Incorporated, 7170 Frederick Banting, St. Laurent, Quebec, Canada H4S 2A1

Received 14 March 2008/Returned for modification 2 May 2008/Accepted 11 July 2008

Oritavancin is a semisynthetic lipoglycopeptide in clinical development for serious gram-positive infections. This study describes the synergistic activity of oritavancin in combination with gentamicin, linezolid, moxifloxacin, or rifampin in time-kill studies against methicillin-susceptible, vancomycin-intermediate, and vancomycin-resistant *Staphylococcus aureus*.

Oritavancin is a semisynthetic lipoglycopeptide in clinical development that has activity against methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci. It differs from other glycopeptides such as vancomycin and teicoplanin in that its bactericidal activity in vitro is rapid and concentration dependent (1). Recent work demonstrated that oritavancin binds avidly to glass and plastic labware surfaces, causing its potency to be significantly underestimated during susceptibility testing and other microbiological assays (3). The Clinical Laboratory Standards Institute (CLSI) recent update to include polysorbate-80 at 0.002% throughout oritavancin broth microdilution testing (9), which limits binding of oritavancin to vessel surfaces, has prompted reevaluation of oritavancin activity in a range of in vitro microbiological assays.

The potential benefits of combination antimicrobial chemotherapy over monotherapy include decreased resistance development, synergistic antibacterial activity, and a broadened antibacterial spectrum (10, 12). Previous studies examining the activity of oritavancin in combinations were performed in the absence of polysorbate-80, which may have affected assay results (5, 15, 17, 20, 22). We have thus revisited oritavancin combination testing using time-kill methodology in the presence of 0.002% polysorbate-80 to determine whether combinations of oritavancin and other antimicrobial agents exhibit synergistic antibacterial activity against methicillin-susceptible *S. aureus* (MSSA), vancomycin-intermediate *S. aureus* (VISA), and vancomycin-resistant *S. aureus* (VRSA).

(Received 14 March 2008/Returned for modification 2 May 2008/Accepted 11 July 2008)
ings were confirmed and extended in the current study: against time-kill methodology without polysorbate-80 (15). These findings shown to be synergistic against two VISA isolates by linezolid, a protein synthesis inhibitor (Table 1).

Energy was not observed with the combination of oritavancin and rifampin overlap those for oritavancin plus gentamicin at 6 and 24 h. *, growth control; à, 0.002 g/ml gentamicin; ô, 0.25 µg/ml linezolid; Ñ, oritavancin plus gentamicin; Ñ, oritavancin plus linezolid; Ñ, oritavancin plus rifampin. (B and C) Oritavancin combinations versus VISA NRS402. *, growth control; ô, 0.13 µg/ml oritavancin; Œ, 0.25 µg/ml gentamicin; Ñ, 0.25 µg/ml linezolid; Ñ, oritavancin plus gentamicin; Ñ, oritavancin plus linezolid; ©, oritavancin plus rifampin. (D) Oritavancin combinations versus VRSA VRS5. *, growth control; ô, 0.13 µg/ml oritavancin; Ô, 0.002 µg/ml rifampin; Ñ, oritavancin plus gentamicin; Ñ, oritavancin plus linezolid; ©, oritavancin plus rifampin.

The combination of oritavancin and gentamicin was previously shown to be synergistic against two VISA isolates by time-kill methodology without polysorbate-80 (15). These findings were confirmed and extended in the current study: against the VISA isolate S. aureus NRS402, oritavancin with gentamicin or linezolid was synergistic (Fig. 1B and C; Table 1); these combinations were bactericidal at the 24-h time point. Orita- vancin in combination with gentamicin or linezolid was also synergistic and bactericidal against the VISA isolate VRSS (Fig. 1D; Table 1). Conceivably, the ability of oritavancin to

![FIG. 1. Time-kill curves of synergistic combinations of oritavancin with gentamicin, linezolid, moxifloxacin, or rifampin against MSSA, VISA and VRSA. Exponential-phase MSSA ATCC 29213, VISA NRS402, or VRSA VRSS was diluted in CAMHB containing 0.002% polysorbate-80 and challenged with the test agents at the indicated concentrations. The single-agent drug concentrations were maintained during combination testing with oritavancin. Viability was enumerated at the indicated time points by serial dilution plating. Each point represents the mean of duplicate determinations. Whereas experiments were performed in triplicate, the time-kill curves presented here are from a single experiment. The limit of detection (200 CFU/ml) is indicated by the dashed lines. (A) Oritavancin combinations versus MSSA ATCC 29213. Note that the points for oritavancin plus rifampin overlap those for oritavancin plus gentamicin at 6 and 24 h. *, growth control; Ò, 0.031 µg/ml oritavancin; Ñ, 0.25 µg/ml gentamicin; ô, 0.063 µg/ml moxifloxacin; ©, 0.008 µg/ml rifampin; Ñ, oritavancin plus gentamicin; Ñ, oritavancin plus linezolid; ©, oritavancin plus rifampin. (B and C) Oritavancin combinations versus VISA NRS402. *, growth control; ô, 0.50 µg/ml oritavancin; Ñ, 0.13 µg/ml gentamicin; Ñ, 0.25 µg/ml linezolid; Ñ, oritavancin plus gentamicin; Ñ, oritavancin plus linezolid; ©, oritavancin plus rifampin. (D) Oritavancin combinations versus VRSA VRS5. *, growth control; ô, 0.13 µg/ml oritavancin; Ô, 0.25 µg/ml gentamicin; Ô, 1 µg/ml linezolid; ©, 0.002 µg/ml rifampin; Ñ, oritavancin plus gentamicin; Ñ, oritavancin plus linezolid; ©, oritavancin plus rifampin.](http://aac.asm.org/)

### TABLE 1. Summary of in vitro time-kill assays of oritavancin combinations against S. aureus isolates

<table>
<thead>
<tr>
<th>Agent</th>
<th>MSSA ATCC 29213</th>
<th>VISA NRS402</th>
<th>VRSA VRSS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORI</td>
<td>0.031</td>
<td>0.50</td>
<td>0.13</td>
</tr>
<tr>
<td>GEN</td>
<td>0.25</td>
<td>0.13</td>
<td>0.25</td>
</tr>
<tr>
<td>LZD</td>
<td>1</td>
<td>0.13</td>
<td>1</td>
</tr>
<tr>
<td>MOX</td>
<td>0.063</td>
<td>0.25</td>
<td>0.002</td>
</tr>
<tr>
<td>RIF</td>
<td>0.008</td>
<td>0.13</td>
<td>1</td>
</tr>
</tbody>
</table>

* Abbreviations: ORI, oritavancin; GEN, gentamicin; LZD, linezolid; MOX, moxifloxacin; RIF, rifampin.

* Concentration of the antimicrobial agent tested as a single agent and used in combination in the time-kill assay.

* Multiple of the broth microdilution MIC (determined as per the CLSI guidelines) of oritavancin or other agent used in combination.

* Values presented are the log 10 change in CFU (a negative value indicates a decrease) at 24 h for the single agent relative to the growth control (C) or for the combination of the indicated agent with oritavancin relative to the most active agent of the combination (A) or the inoculum (I). Values shown are the means of duplicate determinations from a representative experiment repeated at least three times.

* ND, not determined since inherent resistance or nonsusceptibility to the combination agent precluded testing in combination with oritavancin.

* The value after the slash is for oritavancin used in combination with linezolid.

* NA, not applicable.
increase membrane permeability (19) may facilitate entry of gentamicin into the cell, as has been shown with sesquiterpenoids, agents that increase *S. aureus* membrane permeability and increase susceptibility to gentamicin (7). The combination of oritavancin and rifampin was synergistic and bacteriostatic against VR55 at the 24-h time point (Fig. 1D; Table 1). That this combination was also synergistic against MSSA suggests a common killing mechanism of these two strains. We have observed that oritavancin inhibits RNA synthesis in *S. aureus* RN4220, a methicillin-susceptible laboratory strain (4). Loss of the permeability barrier function has been linked to inhibition of macromolecular synthesis, including RNA synthesis (25). Putative leakage of RNA precursors from the cell due to perturbation of cell membrane barrier function by oritavancin, coupled with inhibition of RNA polymerase by rifampin, may explain the synergy between these two agents.

Despite the synergy exhibited by certain combinations of antimicrobial agents in vitro, the overall benefit of combinations in clinical practice remains controversial (12, 16). For example, a recent meta-analysis examining inclusion of an aminoglycoside with a β-lactam for the treatment of endocarditis demonstrated no benefit in clinical outcome over β-lactam monotherapy and increased the frequency of nephrotoxicity (15). However, combination therapy may be beneficial for treatment of certain infections that harbor bacteria either in a tolerant state or in a biofilm, as those associated with indwelling devices (8, 11, 18, 26), or for tuberculosis (24). Recent in vitro findings that the combination of a β-lactam with vancomycin evokes synergistic activity against methicillin-resistant VRSA (23) highlight the potential of antimicrobial combination therapy and thus the importance of in vitro synergy testing.

In conclusion, using newly approved methodology that for broth microdilution assays maintain oritavancin at its intended concentration, we have demonstrated in vitro synergy between oritavancin and representative, clinically used antimicrobial agents against drug-susceptible and -resistant *S. aureus* strains. Future studies in vivo infection models should provide a better understanding of the therapeutic potential of oritavancin combinations.

We thank the scientific support personnel at Targanta Therapeutics for their contributions to this research. We also thank Norris Allen for helpful discussions and critical review of the manuscript.

REFERENCES


